Skip to main content

Drug Interactions between iptacopan and resmetirom

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

iptacopan resmetirom

Applies to: iptacopan and resmetirom

MONITOR: Coadministration of iptacopan may increase the exposure of CYP450 2C8 substrates, which may increase the risk of adverse effects. According to in vitro studies, iptacopan has potential for time-dependent inhibition of the CYP450 2C8 isoenzyme. The interaction may be particularly important for sensitive substrates or those that demonstrate a narrow therapeutic index. However, clinical data evaluating the interaction are not available.

MANAGEMENT: Caution and clinical monitoring are advised if iptacopan is to be used in combination with substrates of CYP450 2C8, particularly sensitive substrates or those with a narrow therapeutic range. The prescribing information for the concomitant medication should also be consulted to assess the benefits versus risks of coadministration with CYP450 2C8 inhibitors and for any dosage adjustments that may be required.

References (3)
  1. (2024) "Product Information. Fabhalta (iptacopan)." Novartis Pharmaceuticals Australia Pty Ltd
  2. (2024) "Product Information. Fabhalta (iptacopan)." Novartis Pharmaceuticals, SUPPL-1
  3. Novartis Pharmaceuticals Canada Inc Product Monograph. Fabhalta (iptacopan) https://pdf.hres.ca/dpd_pm/00078186.PDF

Drug and food interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer